|
1）Silverstein FE, Faich G, Goldstein JL, et al. Gastro-intestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284: 1247-55
|
|
|
|
2）Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006; 119: 255-66
|
|
|
|
|
|
3）Goldstein JL, Chan FK, Lanas A, et al. Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials. Aliment Pharmacol Ther. 2011; 34: 808-16
|
|
|
|
|
|
4）Lee YC, Chang CH, Lin JW, et al. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver Int. 2012; 32: 859-66
|
|
|
|
|
|
5）Tsuji S, Miyoshi H, Tomita T, et al. Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation. Mod Rheumatol. 2012; 22: 353-62
|
|
|
|
|
6）Laharie D, Droz-Perroteau C, Benichou J, et al. Hospitalizations for gastrointestinal and cardio-vascular events in the CADEUS cohort of tradi-tional or Coxib NSAID users. Br J Clin Pharma-col. 2010; 69: 295-302
|
|
|
|
|
|
7）Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009; 104: 728-38
|
|
|
|
|
|
8）Yu Y, Ricciotti E, Scalia R, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med. 2012; 4: 132-54
|
|
|
|
|
|
9）Sakamoto C, Sugano K, Ota S, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol. 2006; 62: 765-72
|
|
|
|
|
|
10）Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001; 344: 967-73
|
|
|
|
|
|
11）Vergara M, Catalan M, Gisbert JP, et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005; 21: 1411-8
|
|
|
|
|
|
12）Sugano K, Kontani T, Katsuo S, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2012; 47: 540-52
|
|
|
|
|
|
13）Sugano K, Kinoshita Y, Miwa H, et al. Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients. Aliment Pharmacol Ther. 2012; 36: 115-25
|
|
|
|
|
|
14）Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002; 347: 2104-10
|
|
|
|
|
|
15）Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology. 2004; 127: 1038-43
|
|
|
|
|
|
16）Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010; 376: 173-9
|
|
|
|
|
|
17）Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007; 369: 1621-6
|
|
|
|
|
|
18）Sung JJ, Chan FK, Chen M, et al. Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut. 2011; 60: 1170-7
|
|
|
|
|
|
19）Lanas A, Garcia-Tell G, Armada B, et al. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med. 2011; 9: 38
|
|
|
|
|
|
20）Hochberg MC, Fort JG, Svensson O, et al. Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin. 2011; 27: 1243-53
|
|
|
|
|
|
21）Cryer BL, Sostek MB, Fort JG, et al. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastro-intestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials. Ann Med. 2011; 43: 594-605
|
|
|
|
|
|
22）Sostek MB, Fort JG, Estborn L, et al. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. Curr Med Res Opin. 2011; 27: 847-54
|
|
|
|
|
|
23）Valkhoff VE, van Soest EM, Mazzaglia G, et al. Adherence to gastroprotection during cyclo-oxygenase-2 inhibitor use and the risk of upper gastrointestinal events: A population-based study. Arthritis Rheum. 2012; 64: 2792-802
|
|
|
|
|
|
24）Morini S, Zullo A, Oliveti D, et al. A very high rate of inappropriate use of gastroprotection for nonsteroidal anti-inflammatory drug therapy in primary care: a cross-sectional study. J Clin Gastroenterol. 2011; 45: 780-4
|
|
|
|
|
|
25）Tsumura H, Fujita T, Tamura I, et al. Association between adherence to evidence-based guidelines for the prescription of non-steroidal anti-inflammatory drugs and the incidence of gastric mucosal lesions in Japanese patients. J Gastroenterol. 2010; 45: 944-51
|
|
|
|
|
|
26）Urayama N, Shiraishi K, Aoyama K, et al. Factors predicting incomplete endoscopic hemostasis in bleeding gastroduodenal ulcers. Hepato-gastroenterology. 2010; 57: 519-23
|
|
|
|
|
|
27）Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012; 107: 345-60; quiz 361
|
|
|
|
|
|
28）Chan FK, Sung JJ, Suen R, et al. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective rando-mized study. Aliment Pharmacol Ther. 1998; 12: 1201-5.
|
|
|
|
|